The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.
DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

ANALYSIS OF CHEMICALS AND PHARMACEUTICAL FORMULATIONS FOR ANTICANCER AGENTS (RFP)
National Cancer Institute
Index: CANCER

COLLECTION AND ANNOTATION OF POPULATION LITERATURE AS A RESEARCH RESOURCE (RFP)
National Institute of Child Health and Human Development
Index: CHILD HEALTH AND HUMAN DEVELOPMENT

KIDNEY AND UROLOGICAL RESEARCH CENTERS (RFA)
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES AND DIGESTIVE AND KIDNEY DISEASES

MINIMALLY INVASIVE TECHNIQUES FOR DETECTION AND QUANTIFICATION OF ATHEROSCLEROTIC LESIONS IN HUMAN CORONARY ARTERIES (RFA)
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD

MOLECULAR BIOLOGY OF LUNG ANTIOXIDANT ENZYME REGULATION (RFA)
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD

ROLE OF NEUROCHEMICALS IN THE CONTROL OF RESPIRATION (RFA)
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD

ONGOING PROGRAM ANNOUNCEMENTS

RESEARCH ON NUTRITION IN SICKLE CELL DISEASE
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD
ANALYSIS OF CHEMICALS AND PHARMACEUTICAL FORMULATIONS FOR ANTICANCER AGENTS

RFP AVAILABLE: NCI-CM-67880-22

P.T. 34; K.W. 1003008, 0740020

National Cancer Institute

RFP No. NCI-CM-67880 will be issued, upon written request from Elizabeth Clark Moore, on or about August 18, 1986, and proposals will be due approximately six weeks thereafter. The contract period is to be five years beginning approximately June 1, 1987. The incumbent contractors are: Midwest Research Institute, Kansas City, Missouri; Research Triangle Institute, Research Triangle Park, North Carolina; and SRI International, Menlo Park, California.

Multiple cost-reimbursement contracts are expected to be awarded to contractors with the capability to evaluate bulk chemicals and formulated drug products for identity, purity, and drug content. Reports of the analytical testing on bulk drugs and dosage forms will be used as a basis for assessing the suitability of bulk drugs or finished dosage forms for use in screening, pharmacology studies, toxicological studies, formulation studies, or for clinical trials. These data will also be supplied to the Food and Drug Administration as part of the NCI/IND filings for new anti-cancer agents.

Historical summaries of the data will be used in preparing specifications for the various bulk pharmaceutical substances. These specifications will be used in procurement actions, as well as for the routine quality control of these materials.

In addition, solubility data will be developed, and selected assay methods will be adapted for the quantitation of drug in plasma. These data will be provided to other contract projects to facilitate formulation development, and to aid in the analytical aspects of pharmacology and toxicological testing.

The Principal Investigator should be trained in Chemistry (Analytical, Pharmaceutical, Organic, etc.), preferably at the Ph.D. level from an accredited school, and must be thoroughly familiar with the analysis and evaluation of bulk pharmaceutical substances and clinical dosage forms. In lieu of the Ph.D., equivalent experience may be acceptable.

Copies of the RFP NCI-CM-67880-22 may be obtained by sending a written request to:

Elizabeth Clark Moore
Contract Specialist
Treatment Contracts Section, Research Contracts Branch
National Cancer Institute
Blair Building, Room 228
Bethesda, Maryland 20892

COLLECTION AND ANNOTATION OF POPULATION LITERATURE AS A RESEARCH RESOURCE

RFP AVAILABLE: RFP-NICHD-DBS-86-13

P.T. 34; K.W. 0413004, 0413000, 1103002, 1004008

National Institute of Child Health and Human Development

The Demographic and Behavioral Sciences Branch, Center for Population Research, National Institute of Child Health and Human Development, has a requirement and plans to issue a Request for Proposals (RFP) entitled "Collection and Annotation of Population Literature as a Research Resource.

Proposals will be solicited for performance of a 5-year contract under which the Contractor shall select all significant works of central demographic relevance from the current world literature of social and biological sciences in western languages and, as appropriate, add citations to population acquisitions from selected major libraries. University.

The Contractor shall prepare complete bibliographical citations with comprehensive abstracts, including translation into English where necessary, standardization of format, control of reference, and preparation of annotation indicative of content and range. The Contractor must integrate citations into a conceptual theme of population research with cross-references by author and geographical indexes for quarterly publication. In addition to preparing final copy
for photo-offset reproduction, citations must also be prepared in machine-readable form for monthly inclusion in POPLINE, the AID (Agency for International Development) supported on-line population information system available through the National Library of Medicine.

This is not a Request for Proposals (RFP). RFP-NICHD-DBS-86-13 will be issued on or about August 20, 1986. Proposals will be due approximately 45 days thereafter. A copy of the RFP may be obtained by written request to:

Mr. Paul J. Duska, Contracting Officer
Contracts Management Section, OGC
National Institute of Child Health and Human Development,
Landow Building, Room 6C25,
7941 Woodmont Ave.
Bethesda, MD 20892

KIDNEY AND UROLOGICAL RESEARCH CENTERS

RFA AVAILABLE: 86-DK-01

P.T. 34; K.W. 0785220, 0715085, 0755030, 0785055, 0710070, 0710030

National Institute of Diabetes and Digestive and Kidney Diseases

Application Receipt Date: December 12, 1986

The Division of Kidney, Urologic and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reannounces a national competition to encourage the submission of research center applications (PSO), which will establish a limited number of Kidney and Urological Research Centers for the purpose of investigating the epidemiology, causes, prevention and treatment of kidney and urinary tract disorders.

I. BACKGROUND

Kidney and urologic diseases account for substantial and increasing morbidity and financial burden in the United States; cumulatively they are responsible for a large number of work days lost and the loss of all or a part of a normal healthy life. Although considerable progress has been made in understanding the basic physiology and pathophysiology of the normal renal and urologic system, there has been little progress in the understanding of fundamental disease processes. Nevertheless, major progress has been made in the management of the clinical sequelae of these diseases. For example, renal dialysis and transplantation have been developed as life-saving procedures and the surgical management of benign prostatic hyperplasia (BPH) has also made substantial progress over the past twenty years. Unfortunately, these advances are not curative procedures and are costly. The proposed multidisciplinary research centers should provide appropriate expertise to investigate the topical areas of immunologically mediated diseases; diabetes mellitus and other endocrine and metabolic disorders; primary renal hypertension; genetic abnormalities; developmental and obstructive disorders; nephrotoxins and toxic cell injury.

II. RESEARCH GOALS AND SCOPE

The emphases of this initiative are threefold: (1) to attract new scientific expertise into the study of the basic mechanisms of kidney and urological diseases; (2) to encourage interdisciplinary research; and (3) to extend these basic investigations into innovative clinical and epidemiologic studies of the causes, therapy and prevention of kidney and urologic disorders. In approaching one or more of the disease processes outlined above, it is anticipated that extensive collaboration will be required between individuals in the basic sciences, including cell biology, molecular biology, immunology, genetics, epidemiology, biochemistry, physiology and pathology with clinical sciences. Thus it is an express intent to engage in the field investigators who currently have research interests that are peripheral to renal and urinary tract research but who may wish to apply their technologies and expertise in exploring new basic areas which may then be applied to clinical research projects. Individual institutions with both basic and clinical research capabilities would qualify for applying; however, the arrangement for inter-institutional collaborative research activities is another means of meeting the intent of this announcement. It is anticipated that the NIDDK will initially fund up to six Centers at a level not to exceed $1 million total costs/year/Center. Therefore, the requested level of direct cost support for the project period should be planned so that when combined with institutional indirect costs, the resulting five year request will not exceed $5 million. The awards resulting from this competition will likely be issued for five years on or about July 1, 1987.
III. MECHANISM OF SUPPORT

Support for this program will be through the grant-in-aid and will be governed by policies of grant programs of the National Institutes of Health. Support for the Centers is contingent upon ultimate receipt of appropriated funds for this purpose.

IV. APPLICATION AND REVIEW PROCEDURES

Center applications in response to this announcement will be evaluated in national competition by a Special Review Committee convened by the NIDDK. Due to time constraints it is unlikely that site visits will be an instrument of the review process. Deadline for the receipt of the applications will be December 12, 1986 and a letter of intent is requested by October 1, 1986. No waiver of the receipt date will be considered and therefore any application arriving later Friday, December 12, 1986 will be returned to the applicant.

V. INQUIRIES

Potential applicants may request additional information and copies of the entire RFA from:

M. J. Scherbenske, Ph.D.
Assistant to the Director for Administration
Renal Physiology/Pathophysiology Program Director
DKUHD-1111
Westwood Building, Room 621
5333 Westbard Avenue
Bethesda, Maryland 20892
Telephone: (301) 496-7458

MINIMALLY INVASIVE TECHNIQUES FOR DETECTION AND QUANTIFICATION OF ATHEROSCLEROTIC LESIONS IN HUMAN CORONARY ARTERIES

RFA Available: 86-HL-31-H
P.T. 34; K.W. 0715040, 0706030, 0607024, 0785190, 0710090, 1003002, 1002004
National Heart, Lung, and Blood Institute
Application Receipt Date: December 15, 1986

BACKGROUND

Coronary artery disease is a major problem in the adult population, resulting in 540,000 deaths each year in the United States. Presently, the definitive procedure for detecting and quantifying lesions in coronary arteries is intraarterial angiography. Techniques for accomplishing this which are less invasive could permit early treatment and monitoring of progression or regression of lesions. A desirable outcome would be a technique which could be applied on an outpatient basis with a considerably reduced cost.

OBJECTIVES AND SCOPE

The goal of this solicitation is the research, development and evaluation of new or improved instrumentation and techniques which are minimally invasive for detection and quantification of atherosclerotic lesions in human coronary arteries having lumen diameters of 2 mm or smaller. Desirable objectives are the resolution of a 25 percent reduction in lumenal area and 0.5 mm in linear dimensions. The ultimate goal is to evaluate the atherosclerotic lesions in vivo in a minimally invasive manner, without need for intraarterial administration of agents, with an accuracy approaching that of a post-mortem examination and to provide the capability of periodically examining the status, progression or regression of lesions.

MECHANISMS OF SUPPORT

The support mechanism for this program will be the traditional, individual research-project grant. Although the financial plans for fiscal year 1987 include $2 million for the total (direct and indirect) costs of this program, award of grants pursuant to this RFA is contingent upon receipt of funds for this purpose. It is anticipated that five to seven awards will be made under this program. The specific amount to be funded will, however, depend on the merit and scope of the applications received and the availability of funds. Since a variety of approaches would represent valid responses to this announcement, it is anticipated that there will be a range of costs among individual grants awarded.
Applications will be reviewed as a single competition by an initial review group convened by the Division of Extramural Affairs, National Heart, Lung, and Blood Institute.

INQUIRIES

Inquiries regarding this announcement may be directed to the program administrator:

Dr. Alan S. Berson
Federal Building, Room 312
National Institutes of Health
Bethesda, Maryland 20892
Telephone: (301) 496-1586

MOLECULAR BIOLOGY OF LUNG ANTIOXIDANT ENZYME REGULATION

RFA AVAILABLE: 86-HL-28-L

P.T. 34; K.W. 1002008, 0710055, 0705065, 1002019, 1002027, 0715165, 1003002

National Heart, Lung, and Blood Institute

Application Receipt Date: February 16, 1987

The Division of Lung Diseases invites grant applications for a single competition for support of research utilizing the techniques of molecular biology to study the mechanisms involved in regulating the activity of antioxidant enzymes in lung cells.

The main purpose of this special grant program is to identify the specific biochemical mechanisms involved in the induction or suppression of antioxidant enzyme activity, and to learn how those mechanisms can be altered in order to augment cellular antioxidant defenses. Among the disciplines and expertise that may be appropriate for this research program are molecular biology, genetics, biochemistry, enzymology, microbiology, and pulmonary medicine.

A letter of intent is requested by November 17, 1986, and the deadline for receipt of applications is February 16, 1987. The earliest award date for successful applications will be in September, 1987. Awards in connection with this announcement will be made to foreign institutions only for research of very unusual merit, need, and promise, and in accordance with Public Health Service policy governing such awards.

Requests for copies of this RFA should be addressed to:

Alfred Small, Ph.D.
Interstitial Lung Diseases Branch
Division of Lung Diseases, NHLBI
Westwood Building, Room 6A09
5333 Westbard Avenue
Bethesda, Maryland 20892
Telephone: (301) 496-7034

ROLE OF NEUROCHEMICALS IN THE CONTROL OF RESPIRATION

RFA AVAILABLE: 86-HL-29-L

P.T. 34; K.W. 0760025, 0705065, 0710085, 1002008, 1003002, 0710100, 0785050

National Heart, Lung, and Blood Institute

Application Receipt Date: March 16, 1987

The Division of Lung Diseases invites grant applications for a single competition for support of research on the role of neurochemicals in the control of respiration in health and disease.

The main purpose of this special grant program is to stimulate new and innovative basic research directed at identifying the endogenous neurochemicals and hormones that act to control breathing, mapping their cellular networks, elucidating their
actions and the mechanisms by which they work. Among the disciplines and expertise that may be appropriate for this research program are respiratory physiology, neurobiology, molecular biology, neuroanatomy, biochemistry, endocrinology, and pharmacology.

A letter of intent is requested by December 15, 1986, and the deadline for receipt of applications is March 16, 1987. Awards in connection with this announcement will be made to foreign institutions only for research of very unusual merit, need, and promise, and in accordance with Public Health Service policy governing such awards.

Requests for copies of this RFA should be addressed to:

James P. Kiley, Ph.D.
Structure and Function Branch
Division of Lung Diseases, NHLBI
5333 Westbard Avenue, Room 6A07
Bethesda, MD 20892
(301) 496-7171

ONGOING PROGRAM ANNOUNCEMENTS

RESEARCH ON NUTRITION IN SICKLE CELL DISEASE

P.T. 34; K.W. 0710095, 0765020, 0785070, 0765005

National Heart, Lung, and Blood Institute

The Division of Blood Diseases and Resources (DBDR), National Heart, Lung, and Blood Institute (NHLBI), encourages grant applications for basic and clinical research on the role of nutrition in sickle cell disease. The field of nutrition is rapidly evolving with better understanding of the importance of vitamins and trace elements in health and disease. Although, our understanding of sickle cell disease at the basic and clinical levels has advanced significantly over the past decade, there is very little known about the relationship of nutritional factors to the clinical manifestations of sickle cell disease.

Attention to nutritional adequacy has been clearly demonstrated to have a beneficial effect in other chronic diseases in children. Specific nutritional programs have been shown to improve growth and development in patients with chronic renal disease and pulmonary diseases, such as cystic fibrosis. Nutritional intervention has been particularly dramatic in improving components of the immune system and growth rates in patients with chronic illness. Similarly, identification of nutritional inadequacies in sickle cell disease patients and the designing of intervention protocols may lead to nutritional programs of benefit to patients with this disorder.

Children with sickle cell disease have delayed growth and sexual maturation and, although these impairments are usually transient, it is possible that nutritional factors play a role. The increased susceptibility to infection in these patients and evidence linking undernutrition, infection and immunodeficiency in other disease states provide a sound rationale for investigating a possible nutritional role in the immune dysfunction seen in patients with sickle cell disease. Energy requirements for basal metabolism may be altered in sickle cell disease, either by chronic anemia, infection, increased urinary loss, organ failure, chronic inflammatory disease or malabsorption, leading to changes in nutrient utilization. These metabolic consequences of sickle cell disease are poorly understood.

Questions relating to energy and protein requirements; the degree of nutritional abnormalities in sickle cell patients; optimum nutritional supplementation needed for optimum growth, development and maturation; causes of failure to thrive in some pediatric patients, even in the presence of adequate caloric intake; and the role of nutritional factors in immune dysfunction and in the wide spectrum of clinical variability, are all important areas for research investigations under this solicitation.

Applicants should use the regular research grant application (PHS 398). There are three receipt dates each year for new applications: February 1, June 1, and October 1. All applications will be assigned by the DRG for review according to the NIH process for regular research grant applications. Secondary review will be by the appropriate National Advisory Council. Applications recommended for approval will compete for available funds with all other approved applications received in the
regular review cycle. However, since the Institute and the NHLBAC consider this subject to be of particular interest, applications responsive to this announcement and assigned to NHLBI will be brought to the special attention of the Council.

If application forms are not available at the institution's business office or central application control office, copies may be requested by writing to the Division of Research Grants (DRG), NIH. In order to identify the application as a response to this program announcement, check "yes" on Item 2 of the application face page with the title NUTRITION IN SICKLE CELL DISEASE. The original and six copies of the application should be mailed to:

Division of Research Grants
National Institutes of Health
Westwood Building - Room 240
Bethesda, Maryland 20892

The programs of the Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, are identified in the Catalog of Federal Domestic Assistance, number 13.839. Awards will be made under the authority of the Public Health Service Act, Section 301 (42 USC 241) and administered under PHS grant policies and Federal regulations, most specifically 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372, or to Health Systems Agency Review.